An update on male hypogonadism therapy

Prasanth N Surampudi, Ronald S. Swerdloff, Christina Wang

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Introduction: Men who have symptoms associated with persistently low serum total testosterone level should be assessed for testosterone replacement therapy. Areas covered: Acute and chronic illnesses are associated with low serum testosterone and these should be recognized and treated. Once the diagnosis of male hypogonadism is made, the benefits of testosterone treatment usually outweigh the risks. Without contraindications, the patient should be offered testosterone replacement therapy. The options of testosterone delivery systems (injections, transdermal patches/gels, buccal tablets, capsules and implants) have increased in the last decade. Testosterone improves symptoms and signs of hypogonadism such as sexual function and energy, increases bone density and lean mass and decreases visceral adiposity. In men who desire fertility and who have secondary hypogonadism, testosterone can be withdrawn and the patients can be placed on gonadotropins. New modified designer androgens and selective androgen receptor modulators have been in preclinical and clinical trials for some time. None of these have been assessed for the treatment of male hypogonadism. Expert opinion: Despite the lack of prospective long-term data from randomized, controlled clinical trials of testosterone treatment on prostate health and cardiovascular disease risk, the available evidence suggests that testosterone therapy should be offered to symptomatic hypogonadal men.

Original languageEnglish (US)
Pages (from-to)1247-1264
Number of pages18
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Eunuchism
Testosterone
Therapeutics
Hypogonadism
Transdermal Patch
Cheek
Adiposity
Expert Testimony
Androgen Receptors
Serum
Gonadotropins
Bone Density
Androgens
Tablets
Signs and Symptoms
Capsules
Fertility
Prostate
Chronic Disease
Cardiovascular Diseases

Keywords

  • Alternative methods of treatment
  • Gonadotropin treatment
  • Primary and secondary hypogonadism
  • Testosterone replacement

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

An update on male hypogonadism therapy. / Surampudi, Prasanth N; Swerdloff, Ronald S.; Wang, Christina.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 9, 2014, p. 1247-1264.

Research output: Contribution to journalReview article

Surampudi, Prasanth N ; Swerdloff, Ronald S. ; Wang, Christina. / An update on male hypogonadism therapy. In: Expert Opinion on Pharmacotherapy. 2014 ; Vol. 15, No. 9. pp. 1247-1264.
@article{33586244084545c493a4bca52080a50f,
title = "An update on male hypogonadism therapy",
abstract = "Introduction: Men who have symptoms associated with persistently low serum total testosterone level should be assessed for testosterone replacement therapy. Areas covered: Acute and chronic illnesses are associated with low serum testosterone and these should be recognized and treated. Once the diagnosis of male hypogonadism is made, the benefits of testosterone treatment usually outweigh the risks. Without contraindications, the patient should be offered testosterone replacement therapy. The options of testosterone delivery systems (injections, transdermal patches/gels, buccal tablets, capsules and implants) have increased in the last decade. Testosterone improves symptoms and signs of hypogonadism such as sexual function and energy, increases bone density and lean mass and decreases visceral adiposity. In men who desire fertility and who have secondary hypogonadism, testosterone can be withdrawn and the patients can be placed on gonadotropins. New modified designer androgens and selective androgen receptor modulators have been in preclinical and clinical trials for some time. None of these have been assessed for the treatment of male hypogonadism. Expert opinion: Despite the lack of prospective long-term data from randomized, controlled clinical trials of testosterone treatment on prostate health and cardiovascular disease risk, the available evidence suggests that testosterone therapy should be offered to symptomatic hypogonadal men.",
keywords = "Alternative methods of treatment, Gonadotropin treatment, Primary and secondary hypogonadism, Testosterone replacement",
author = "Surampudi, {Prasanth N} and Swerdloff, {Ronald S.} and Christina Wang",
year = "2014",
doi = "10.1517/14656566.2014.913022",
language = "English (US)",
volume = "15",
pages = "1247--1264",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - An update on male hypogonadism therapy

AU - Surampudi, Prasanth N

AU - Swerdloff, Ronald S.

AU - Wang, Christina

PY - 2014

Y1 - 2014

N2 - Introduction: Men who have symptoms associated with persistently low serum total testosterone level should be assessed for testosterone replacement therapy. Areas covered: Acute and chronic illnesses are associated with low serum testosterone and these should be recognized and treated. Once the diagnosis of male hypogonadism is made, the benefits of testosterone treatment usually outweigh the risks. Without contraindications, the patient should be offered testosterone replacement therapy. The options of testosterone delivery systems (injections, transdermal patches/gels, buccal tablets, capsules and implants) have increased in the last decade. Testosterone improves symptoms and signs of hypogonadism such as sexual function and energy, increases bone density and lean mass and decreases visceral adiposity. In men who desire fertility and who have secondary hypogonadism, testosterone can be withdrawn and the patients can be placed on gonadotropins. New modified designer androgens and selective androgen receptor modulators have been in preclinical and clinical trials for some time. None of these have been assessed for the treatment of male hypogonadism. Expert opinion: Despite the lack of prospective long-term data from randomized, controlled clinical trials of testosterone treatment on prostate health and cardiovascular disease risk, the available evidence suggests that testosterone therapy should be offered to symptomatic hypogonadal men.

AB - Introduction: Men who have symptoms associated with persistently low serum total testosterone level should be assessed for testosterone replacement therapy. Areas covered: Acute and chronic illnesses are associated with low serum testosterone and these should be recognized and treated. Once the diagnosis of male hypogonadism is made, the benefits of testosterone treatment usually outweigh the risks. Without contraindications, the patient should be offered testosterone replacement therapy. The options of testosterone delivery systems (injections, transdermal patches/gels, buccal tablets, capsules and implants) have increased in the last decade. Testosterone improves symptoms and signs of hypogonadism such as sexual function and energy, increases bone density and lean mass and decreases visceral adiposity. In men who desire fertility and who have secondary hypogonadism, testosterone can be withdrawn and the patients can be placed on gonadotropins. New modified designer androgens and selective androgen receptor modulators have been in preclinical and clinical trials for some time. None of these have been assessed for the treatment of male hypogonadism. Expert opinion: Despite the lack of prospective long-term data from randomized, controlled clinical trials of testosterone treatment on prostate health and cardiovascular disease risk, the available evidence suggests that testosterone therapy should be offered to symptomatic hypogonadal men.

KW - Alternative methods of treatment

KW - Gonadotropin treatment

KW - Primary and secondary hypogonadism

KW - Testosterone replacement

UR - http://www.scopus.com/inward/record.url?scp=84901034886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901034886&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.913022

DO - 10.1517/14656566.2014.913022

M3 - Review article

VL - 15

SP - 1247

EP - 1264

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 9

ER -